Evidence map›Paper›PMID 37340421›Full record

ArticleJournal of translational medicine2023

NIPSNAP1 directs dual mechanisms to restrain senescence in cancer cells.

Enyi Gao, Xiaoya Sun, Rick Francis Thorne, Xu Dong Zhang, Jinming Li, Fengmin Shao, Jianli Ma, Mian Wu

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. UBE4B Mediates Mitophagy via NIPSNAP1 Ubiquitination and NDP52 Recruitment.International journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. N6-methyladenosine readerWorld journal of gastroenterology · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Pitfalls of Mitochondrial Redox Signaling Research.Antioxidants (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Enyi GaoTranslational Research Institute, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, Zhengzhou, 450046, China.
Xiaoya SunSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Rick Francis ThorneHenan Provincial People's Hospital, Zhengzhou University, Zhengzhou, 450003, China.
Xu Dong ZhangHenan Provincial People's Hospital, Zhengzhou University, Zhengzhou, 450003, China.
Jinming LiHenan Provincial People's Hospital, Zhengzhou University, Zhengzhou, 450003, China.
Fengmin ShaoHenan Provincial People's Hospital, Zhengzhou University, Zhengzhou, 450003, China. fengminshao@126.com.
Jianli MaDepartment of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China. 943328544@qq.com.
Mian WuTranslational Research Institute, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, Zhengzhou, 450046, China. wumian@ustc.edu.cn.
Henan Provincial People's Hospital · CNZhengzhou University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the executive pathways of senescence are known, the underlying control mechanisms are diverse and not fully understood, particularly how cancer cells avoid triggering senescence despite experiencing exacerbated stress conditions within the tumor microenvironment.

methodsMass spectrometry (MS)-based proteomic screening was used to identify differentially regulated genes in serum-starved hepatocellular carcinoma cells and RNAi employed to determine knockdown phenotypes of prioritized genes. Thereafter, gene function was investigated using cell proliferation assays (colony-formation, CCK-8, Edu incorporation and cell cycle) together with cellular senescence assays (SA-β-gal, SAHF and SASP). Gene overexpression and knockdown techniques were applied to examine mRNA and protein regulation in combination with luciferase reporter and proteasome degradation assays, respectively. Flow cytometry was applied to detect changes in cellular reactive oxygen species (ROS) and in vivo gene function examined using a xenograft model.

resultsAmong the genes induced by serum deprivation, NIPSNAP1 was selected for investigation. Subsequent experiments revealed that NIPSNAP1 promotes cancer cell proliferation and inhibits P27-dependent induction of senescence via dual mechanisms. Firstly, NIPSNAP1 maintains the levels of c-Myc by sequestering the E3 ubiquitin ligase FBXL14 to prevent the proteasome-mediated turnover of c-Myc. Intriguingly, NIPSNAP1 levels are restrained by transcriptional repression mediated by c-Myc-Miz1, with repression lifted in response to serum withdrawal, thus identifying feedback regulation between NIPSNAP1 and c-Myc. Secondly, NIPSNAP1 was shown to modulate ROS levels by promoting interactions between the deacetylase SIRT3 and superoxide dismutase 2 (SOD2). Consequent activation of SOD2 serves to maintain cellular ROS levels below the critical levels required to induce cell cycle arrest and senescence. Importantly, the actions of NIPSNAP1 in promoting cancer cell proliferation and preventing senescence were recapitulated in vivo using xenograft models.

conclusionsTogether, these findings reveal NIPSNAP1 as an important mediator of c-Myc function and a negative regulator of cellular senescence. These findings also provide a theoretical basis for cancer therapy where targeting NIPSNAP1 invokes cellular senescence.

Indexed as

NeoplasmsProteasome Endopeptidase ComplexCell LineCellular SenescenceHumansIntercellular Signaling Peptides and ProteinsProteomicsReactive Oxygen SpeciesTumor MicroenvironmentIntercellular Signaling Peptides and ProteinsNIPSNAP1 protein, humanProteasome Endopeptidase ComplexReactive Oxygen SpeciesAcetylationCellular senescencec-MycFBXL14NIPSNAP1ROSSIRT3SOD2

Identifiers

PMID37340421
PMCPMC10280965
OpenAlexW4381337668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.